NCT00726648View on ClinicalTrials.gov

CDP323 Biomarker Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

CDP323

50mg capsules, 100mg bid for 4 weeks

DRUG

CDP323

250mg capsules, 500mg bid for 4 weeks

DRUG

CDP323

250mg capsules, 1000mg bid for 4 weeks

DRUG

CDP323

250mg capsules, 1000mg daily for 4 weeks

DRUG

Placebo

placebo capsules for 4 weeks

Trial Locations (2)

Unknown

Tooting

Croydon

Sponsors

Lead Sponsor

UCB Pharma

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

UCB Pharma

INDUSTRY